Skip to main content
Publications
Arana A , Pottegard A, Kuiper J, Booth H, Reutfors J, Calingaert B , Lund LC, Crellin E, Schmitt-Egenolf M, Kaye J, Gembert K, Rothman K , Kieler H, Dedman D, Houben E, Gutierrez L , Hallas J, Perez-Gutthann S . Long-term risk of skin cancer and lymphoma in users of topical tacrolimus and pimecrolimus: final results from the extension of the cohort study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE) . Clin Epidemiol. 2021 Dec 29;2021(13):1141-53. doi: 10.2147/CLEP.S331287
Fortuny J , von Gersdorff G, Lassalle R, Linder M, Overbeek J, Reinold J, Toft G, Timmer A, Dress J, Blin P, Droz-Perroteau C, Ehrenstein V, Franzoni C , Herings R, Kollhorst B, Moore N, Odsbu I, Perez-Gutthann S , Schink T, Rascher K, Rasouliyan L, Rothman KJ , Saigi-Morgui N , Schaller M, Smits E, Forstner M, Intravenous Iron Consortium, Benichou J, Bircher AJ, Garbe E, Rampton DS, Gutierrez L . Use of intravenous iron and risk of anaphylaxis: a multinational observational post-authorisation safety study in Europe . Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1447-57. doi: 10.1002/pds.5319
Hoffman V, Hallas J, Linder M, Margulis AV , Suehs BT, Arana A , Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S , Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD. Cardiovascular risk in users of mirabegron relative to users of antimuscarinic treatments for overactive bladder: findings from a non-interventional, real-world data safety study . Presented at the Virtual ICPE 2021 Conference; August 24, 2021. Previously presented at the 2020 Virtual American Heart Association’s Scientific Sessions.
Kuiper JG, Franzoni C , Ehrenstein V, Gini R, Haug U, Moore N, Droz-Perroteau C, Bolibar B, Giner-Soriano M, Hallas J, MacDonald T, Sturkenboom M, Klungel OH, Perez-Gutthann S , Herings RM. The SIGMA Consortium: a new era of collaboration to study the safety and effectiveness of medical interventions . Poster presented at the Virtual ICPE 2021 Conference; August 23, 2021.
Hoffman V , Hallas J, Linder M, Margulis AV , Suehs BT, Arana A , Phiri K, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S , Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD, mirabegron PMR-PASS study group. Cardiovascular risk in users of mirabegron compared with users of antimuscarinic treatments for overactive bladder: findings from a non-interventional, multinational, cohort study . Drug Saf. 2021 Aug;44(8):899-915. doi: 10.1007/s40264-021-01095-7
Phiri K, Hallas J, Linder M, Margulis A , Suehs B, Arana A , Bahmanyar S, Hoffman V , Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S , Kristiansen NS, Appenteng K, de Vogel S, Seeger J. A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder . Curr Med Res Opin. 2021 May;37(5):867-77. doi: 10.1080/03007995.2021.1891035
Arana A , Margulis AV , Varas-Lorenzo C, Bui CL , Gilsenan A , McQuay LJ, Reynolds M , Rebordosa C , Franks B, de Vogel S, Appenteng K, Perez-Gutthann S . Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom . Pharmacoepidemiol Drug Saf. 2021 Feb;30(2):237-47. doi: 10.1002/pds.5150
Kaye JA, Castellsague J, Bui CL , Calingaert B , McQuay L, Riera Guardia N , Saltus CW , Quinlan S, Holick CN, Wahl PM, Rothman KJ , Wallander MA, Perez-Gutthann S . Case screening and validation in a population-based study of antimicrobial use and acute liver injury . Presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 14, 2011. Chicago, IL. [abstract] Pharmacoepidemiol Drug Saf. 2011 Aug 12; 20(S1):S5-6. doi: 10.1002/pds.2206
Castellsague J, Pisa F, Rosolen V, Riera-Guardia N , Giangreco M, Clagnan E, Tosolini F, Zanier L, Barbone F, Perez-Gutthann S . Use of nimesulide, other nsaids and the risk of upper gastrointestinal complications in Friuli Venezia Giulia, Italy. Analysis of cases with codes with high positive predictive value . Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2011. Chicago, IL. [abstract] Pharmacoepidemiol Drug Saf. 2011 Aug; 20(S1):S178.
Pisa F, Drigo D, Riera-Guardia N , Castellsague J, Rosolen V, Clagnan E, Tosolini F, Zanier L, Perez-Gutthann S , Barbone F. Validation of primary and secondary ICD-9-cm codes for upper gastrointestinal complications in Friuli Venezia Giulia, Italy . Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 1, 2011. [abstract] Pharmacoepidemiol Drug Saf. 20(Suppl. 1):S172.